Key facts
- This page summarizes Caroline Dorsa's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2022, 18:26.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
Footnote F2
This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.